Adam F. : Vertex will now dominate cystic fibrosis. Peak Sales In Billions. posted.
Worth Repeating: Vertex Is the Next Gilead Sciences
BY Adam Feuerstein | 04/19/13
Analysts are rushing to upgrade and slap triple-digit price targets on Vertex because it now appears more likely that the company's cystic fibrosis drug franchise will prove effective for a large swath of the 70,000 people with the genetic lung disease worldwide. Peak sales could easily top $5-6 billion.
Last May, when Vertex released interim results from its combination therapy for cystic fibrosis, I wrote a column explaining why investors should look at Vertex as the next Gilead Sciences (GILD). Like Gilead dominates HIV therapy (and perhaps hepatitis C therapy soon), Vertex will now dominate cystic fibrosis.